Orna Therapeutics Announces Acquisition of ReNAgade Therapeutics


We’re rapidly and relentlessly advancing transformational RNA medicines.

See the headlines our progress has inspired.

January 2024

ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference

Cambridge, Mass., January 4, 2024 – ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com

Investor Relations Contact:

Emily Brabbit, Argot Partners
(212) 600-1902

Media Relations Contact:

Sarah Sutton, Argot Partners
(212) 600-1902

“RNA without limits”, “Deliver-Code-Edit-Insert” are trademarks of ReNAgade Therapeutics, Inc.